HGH Fragment 176-191 vs Retatrutide
A side-by-side research comparison of HGH Fragment 176-191 and Retatrutide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | HGH Fragment 176-191 | Retatrutide |
|---|---|---|
| Full name | Human Growth Hormone Fragment 176-191 | Retatrutide (Triple Agonist GIP/GLP-1/Glucagon) |
| Category | Weight Management | Weight Management |
| Status | Research compound | Phase 3 Clinical Trial |
| Mechanism | Mimics lipolytic action of HGH by stimulating beta-3 adrenergic receptors on adipocytes, increasing cyclic AMP and hormone-sensitive lipase activity. Does not affect IGF-1. | Triple agonism creates synergistic metabolic effects. Glucagon activation increases energy expenditure and hepatic fat oxidation while GLP-1/GIP reduce appetite and improve insulin sensitivity. |
| Molecular weight | 1,817 Da | 5,200 Da (approximate) |
| Half-life | 3-4 hours | 6 days |
| Bioavailability | High (SubQ) | High (SubQ) |
| Typical dose | 250-500 mcg | 1-2 mg → titrate up to 12 mg |
| Frequency | 1-2x daily | Once weekly |
| Route | Subcutaneous | Subcutaneous injection |
HGH Fragment 176-191 reported benefits
- Targeted fat loss
- No IGF-1 elevation
- No glucose impairment
- No bone/organ growth effects
- Improved body composition
Retatrutide reported benefits
- Unprecedented weight loss (~24%)
- Significant liver fat reduction
- Improved cardiovascular markers
- Enhanced energy expenditure
- Superior glycemic control
Related comparisons
Research and educational reference only. Not medical advice.